Your browser doesn't support javascript.
loading
Pain assessment for chronic lower back pain: performance of the PAL-S and PAL-I patient-reported measures for symptoms and impacts.
Bushnell, Donald M; Martin, Mona L; Eerdekens, Mariёlle; Christoph, Annette; Kralidis, Georg; Liedgens, Hiltrud.
Afiliação
  • Bushnell DM; Health Research Associates, Inc, Mountlake Terrace, WA, USA.
  • Martin ML; Health Research Associates, Inc, Mountlake Terrace, WA, USA.
  • Eerdekens M; Grünenthal GmbH, Aachen, Germany.
  • Christoph A; Grünenthal GmbH, Aachen, Germany.
  • Kralidis G; Grünenthal GmbH, Aachen, Germany.
  • Liedgens H; Grünenthal GmbH, Aachen, Germany.
Curr Med Res Opin ; 36(5): 853-863, 2020 05.
Article em En | MEDLINE | ID: mdl-32175771
Objective: The Patient Assessment for Low Back Pain-Symptoms (PAL-S) and the Patient Assessment for Low Back Pain-Impacts (PAL-I) were developed to incorporate patient perspective of treatment benefit in chronic low back pain (cLBP) trials. This study documents psychometric measurement properties of the PAL-S and PAL-I.Methods: In this multicenter, observational study, eligible participants clinically diagnosed with cLBP provided sociodemographic information and completed PAL measures and other patient-reported outcome measures of pain and/or disability. Confirmatory factor analyses (CFA), construct validity, and reliability were assessed.Results: The 104 participants were 61% female, 89% white, and mean age of 55 years; mean cLBP duration was 11.4 (range 0-47) years. Using painDETECT scores, 36.5% reported small likelihood of neuropathic pain, 30.8% reported unclear likelihood, and 32.7% reported definite likelihood. Persistent pain with pain attacks was reported by 38.5% of participants. CFA confirmed single components with adequate fit indices. Cronbach's alpha was 0.83 (PAL-S) and 0.87 (PAL-I), indicating reliable scales. Intraclass correlation coefficients (test-retest reproducibility, n = 44) were 0.81 (PAL-S) and 0.85 (PAL-I). PAL-S score correlation was 0.49 with Roland-Morris Disability Questionnaire (RMDQ) and 0.77 with Neuropathic Pain Symptom Inventory (NPSI). PAL-I correlated at 0.73 with RMDQ and -0.60 with Medical Outcomes Study (MOS)-36 Bodily Pain. Both measures significantly differentiated between pain intensity levels (based on numeric response scale) and painDETECT groups.Conclusion: The PAL-S and PAL-I generated highly reliable scores with substantial evidence of construct validity. Routine use of these measures in treatment trials will enhance comparability of LBP-related symptom and impact results, including patient perspective of treatment benefit.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medição da Dor / Dor Lombar / Dor Crônica / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medição da Dor / Dor Lombar / Dor Crônica / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido